Protalix BioTherapeutics (PLX) Corporate presentation summary

Strategic vision and leadership

• Focused on transforming rare disease treatment through innovative biotherapeutics.

• Led by an experienced executive team with deep expertise in pharma, R&D, and business development.

• Board of Directors includes industry veterans with backgrounds in global pharma and biotech.

Commercial portfolio and partnerships

• Two approved enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease.

• Elfabrio approved in the US, EU, and other markets; Elelyso approved in 23 markets.

• Strategic partnerships with Chiesi, Pfizer, and Fiocruz drive commercialization and revenue.

• Elfabrio offers unique every-4-weeks dosing in the EU, improving patient quality of life.

Financial performance and growth

• Achieved profitability with $22.1M net income in H1 2026.

• Revenues reached $53.6M YTD 2026, driven by Elfabrio sales and milestone payments.

• Cash position of $40.7M as of June 30, 2026, with no debt or warrants.

• Projected consistent revenue growth and significant milestone payments in the mid- and long-term.